Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Because we have determined that the Axoguard HA+ Nerve Protector TM does not meet the substantial clinical improvement criterion, we will not address in this final rule with comment period whether the technology meets the cost criterion required for transitional pass-through payment for devices
As indicated in that rule, we proposed this temporary payment exception to mitigate short-term instability and payment fluctuations that can negatively impact hospitals consistent with principles of certainty and predictability under prospective payment systems. To address these same concerns under the OPPS, we correspondingly proposed a transitional payment exception for CY 2026 under the OPPS using our equitable adjustment authority under section 1833(t)(2)(E) of the Act
The establishment of the clinical outcome(s) a peptide should deliver
The condition is iron deficiency, not iron deficiency anemia
US$ 29.34
US$ 29.71
US$ 20.62
US$ 27.36
